London. Do-Coop Technologies Ltd. of Israel is the recipient of Frost & Sullivan's 2004 Enabling Technology Award for nanomedicine. The award commends Do-Coop Technologies' efforts to develop a unique class of nano-
reagents, with the potential to significantly enhance the efficiency and accuracy of diagnostic test kits and
drug screening processes.
Deploying its proprietary
nanotechnology, Do-Coop's innovative, high quality aqueous nano-reagents 'Neowater' and 'Ze-Nox' are poised to make notable contributions to the industry in terms of adoption, change and competitive posture. Both these product technologies offer the prospect of providing up to 10-fold enhancement in the price-performance ratio, and in some instances, facilitating novel, next-generation applications.
Neowater can be incorporated into existing kits or protocols, and deliver improved functioning with minor protocol adjustments. In addition to offering significant performance enhancements, Do-Coop's technologies are also economical and environmentally friendly.
"Essentially a 'revolutionary' product technology, Neowater is set to impact the research and diagnostic test kits sector by delivering the next-generation kits, which promise higher sensitivity and higher yield at lower prices," remarks
Frost & Sullivan Research Manager Girish Solanki.
The ability to enable high performance in DNA uptake, reduce bacteriophage reaction times, improve the immobilisation of
proteins or
oligonucleotides to solid phase matrices and be used a stabilising buffer for
Enzyme storage has reinforced Neowater's impact on the industry. By allowing for a high degree of immobilisation and surface wetting, Neowater has helped realise nano-volume test kits/chips.
In contrast to Neowater, Ze-Nox represents a 'facilitative' product technology that appreciably enhances the effectiveness of drug screening, and also increases the number of post-screening compounds by reducing their
toxicity.
Ze-Nox can also potentially assist in overcoming anti-microbial resistance for certain
antibiotics as well as dramatically improving the solubility of certain drug compounds. Due to its high surface affinity and high
water binding capability, Ze-Nox, like Neowater has the capacity to facilitate 'nano-volume medicine'.
"With their potential to significantly enhance the efficiency, accuracy and throughput of research and diagnostic test kits and the drug screening process itself, Neowater and Ze-Nox are set to redefine standards in the emerging field of nanomedicine," notes Mr. Solanki.
This, in combination with the quality and depth of its R&D programme, and its pioneering role in advancing these 'enabling' product technologies make Do-Coop Technologies Ltd., the undisputed choice for the 2004 Frost & Sullivan Award for Enabling Technology in nanomedicine.